Chip Outlook Gets Cloudier

Motley Fool Money

Early is not always better.

(00:21) Jason Moser and Mary Long discuss the semiconductor supply chain, ASML earnings, and what’s ailing the pharmacy industry.

Then, (16:40) Motley Fool contributor Brian Orelli joins for a look at how the genetic testing company 23andme went from a $6 billion valuation to a penny stock in a mere three years … and where the company (and its data) might go from here.


Vote for Motley Fool Money in the 2024 Signal Awards for Best Money and Finance podcast: https://vote.signalaward.com/PublicVoting#/2024/shows/general/money-finance


Learn more about the Range Rover Sport at www.landroverusa.com


Companies discussed: ASML, WBA, CVS, ME, GSK

Host: Mary Long

Guests: Jason Moser, Brian Orelli

Producer: Ricky Mulvey

Engineers: Tim Sparks, Rick Engdahl

Learn more about your ad choices. Visit megaphone.fm/adchoices

2024-10-16 30 min

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in

Chapters

No chapters available.